Literature DB >> 10846111

Genetic analysis of a poliovirus/hepatitis C virus (HCV) chimera: interaction between the poliovirus cloverleaf and a sequence in the HCV 5' nontranslated region results in a replication phenotype.

W D Zhao1, F C Lahser, E Wimmer.   

Abstract

Internal ribosomal entry sites (IRESs) can function in foreign viral genomes or in artificial dicistronic mRNAs. We describe an interaction between the wild-type hepatitis C virus (HCV)-specific sequence and the poliovirus (PV) 5'-terminal cloverleaf in a PV/HCV chimeric virus (containing the HCV IRES), resulting in a replication phenotype. Either a point mutation at nucleotide (nt) 29 or a deletion up to nt 40 in the HCV 5' nontranslated region relieved the replication block, yielding PV/HCV variants replicating to high titers. Fortuitous yet crippling interactions between an IRES and surrounding heterologous RNA must be considered when IRES-based dicistronic expression vectors are being constructed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846111      PMCID: PMC112126          DOI: 10.1128/jvi.74.13.6223-6226.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Polioviruses containing picornavirus type 1 and/or type 2 internal ribosomal entry site elements: genetic hybrids and the expression of a foreign gene.

Authors:  L Alexander; H H Lu; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

2.  A functional ribonucleoprotein complex forms around the 5' end of poliovirus RNA.

Authors:  R Andino; G E Rieckhof; D Baltimore
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

3.  Cell-free, de novo synthesis of poliovirus.

Authors:  A Molla; A V Paul; E Wimmer
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

4.  A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation.

Authors:  S K Jang; H G Kräusslich; M J Nicklin; G M Duke; A C Palmenberg; E Wimmer
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 5.  Genetics of poliovirus.

Authors:  E Wimmer; C U Hellen; X Cao
Journal:  Annu Rev Genet       Date:  1993       Impact factor: 16.830

6.  Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo.

Authors:  S K Jang; M V Davies; R J Kaufman; E Wimmer
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Poliovirus/Hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides.

Authors:  W D Zhao; E Wimmer; F C Lahser
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Internal ribosome entry site within hepatitis C virus RNA.

Authors:  K Tsukiyama-Kohara; N Iizuka; M Kohara; A Nomoto
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Cardioviral internal ribosomal entry site is functional in a genetically engineered dicistronic poliovirus.

Authors:  A Molla; S K Jang; A V Paul; Q Reuer; E Wimmer
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

10.  Poliovirus RNA synthesis utilizes an RNP complex formed around the 5'-end of viral RNA.

Authors:  R Andino; G E Rieckhof; P L Achacoso; D Baltimore
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  12 in total

1.  5' cloverleaf in poliovirus RNA is a cis-acting replication element required for negative-strand synthesis.

Authors:  D J Barton; B J O'Donnell; J B Flanegan
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  Replication of poliovirus RNA with complete internal ribosome entry site deletions.

Authors:  Kenneth E Murray; Benjamin P Steil; Allan W Roberts; David J Barton
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6, facilitate hepatitis C virus replication.

Authors:  Chon Saeng Kim; Su Kyoung Seol; Ok-Kyu Song; Ji Hoon Park; Sung Key Jang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication.

Authors:  P Friebe; V Lohmann; N Krieger; R Bartenschlager
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 5.  Emergency Services of Viral RNAs: Repair and Remodeling.

Authors:  Vadim I Agol; Anatoly P Gmyl
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-14       Impact factor: 11.056

6.  Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system.

Authors:  Sang-Gu Lee; Dae-You Kim; Byung-Hwa Hyun; Yong-Soo Bae
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Long-range RNA-RNA interaction between the 5' nontranslated region and the core-coding sequences of hepatitis C virus modulates the IRES-dependent translation.

Authors:  Yoon Ki Kim; Song Hee Lee; Chon Saeng Kim; Su Kyoung Seol; Sung Key Jang
Journal:  RNA       Date:  2003-05       Impact factor: 4.942

8.  Genetic analysis of a poliovirus/hepatitis C virus chimera: new structure for domain II of the internal ribosomal entry site of hepatitis C virus.

Authors:  W D Zhao; E Wimmer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Role of the 5'-proximal stem-loop structure of the 5' untranslated region in replication and translation of hepatitis C virus RNA.

Authors:  Guangxiang Luo; Shaojie Xin; Zhaohui Cai
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

10.  Poliovirus 5'-terminal cloverleaf RNA is required in cis for VPg uridylylation and the initiation of negative-strand RNA synthesis.

Authors:  T Lyons; K E Murray; A W Roberts; D J Barton
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.